Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Secondary Endpoints
Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Secondary Endpoints
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.